When PRMT6 is inhibited, MAPK signaling is stimulated, improving the stemness of CD133+ LCSCs.49 About 80 to 90% of HCC patients have cirrhosis due to long-term inflammation of the liver.50 The primary initiator of inflammation associated with liver cancer is the death of epithelial cells. Here, PRMT6 is linked to hepatocellular carcinoma.